Paola Guglielmelli

Has grant

Associate professor

Università degli Studi di Napoli Federico II

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Paola Guglielmelli is an Associate Professor at Università degli Studi di Firenze, Italy. Her research areas include myeloproliferative neoplasms, with recent publications focusing on the genetic determinants of MPN subtypes, management strategies for polycythemia vera, and advancements in therapeutic approaches for myelofibrosis. She has contributed significantly to the understanding of cellular origins in hematological malignancies, as reflected in her recent articles.

Recent Grants

Grant: Close

Personalized medicine program on myeloid neoplasms: characterization of the patient's genome for clinical decision making and systematic collection of real world data to improve quality of health care

Open Date: 2020-11-01

Close Date: 2023-11-01

Grant: Close

Exploiting mutated calreticulin for diagnostic and therapeutic purposes in chronic myeloproliferative neoplasms

Open Date: 2015-01-01

Close Date:

Grant: Close

CLONAL HETEROGENEITY AND CLONAL PROGRESSION IN THE LEUKEMIC TRANSFORMATION OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Open Date: 2014-11-01

Close Date:

Grant: Close

Role of coding and non coding RNA in chronic myeloproliferative neoplasms: from bioinformatics to translational research

Open Date: 2012-09-01

Close Date:

Grant: Close

studio del ruolo del microRNA-16 nella patogenesi della policitemia vera

Open Date: 2011-01-01

Close Date: 2011-12-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (7)

Niccolò Bartalucci

University of Florence

ITALY

View details

Giacomo Coltro

University of Florence

ITALY

View details

Massimiliano BONIFACIO

University of Verona

ITALY

View details

Giuseppe Alberto Maria PALUMBO

Associate Professor of Hematology

Università degli Studi di Napoli Federico II

ITALY

View details

Matteo Giovanni Della Porta

Head

Center for Accelerating Leukeima/Lymphoma Research (CALR)

ITALY

View details

haifa kathrin al-ali

University Hospital Halle (Saale)

GERMANY

View details

Rossella Manfredini

Full Professor

University of Modena and Reggio Emilia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Paola Guglielmelli

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Recommendations for best management of polycythemia vera in Italy: a Delphi consensus statement

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and mature plasmacytoid dendritic cell proliferation (MPDCP): the same cell of origin from a clonal haematopoiesis of indeterminate potential (CHIP)?

Genome-wide analysis defines genetic determinants of MPN subtypes and identifies a sex-specific association at CDH22/CD40

Correction: A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms

A novel approach for highly sensitive and rapid identification of HMGA2 submicroscopic deletions in myeloproliferative neoplasms

Early intervention with ruxolitinib improves spleen response in patients with myelofibrosis

When and how to transplant in myelofibrosis – recent trends

Cytopenic overt primary myelofibrosis at presentation: Analysis of outcomes in the prospective, real‐world ERNEST‐2 registry

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registries

Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study

Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

Collaborators (7)

Niccolò Bartalucci

Giacomo Coltro

Massimiliano BONIFACIO

Giuseppe Alberto Maria PALUMBO

Matteo Giovanni Della Porta

haifa kathrin al-ali

Rossella Manfredini

Make your next move.